The Weight-Loss Drug That Cut Heart Attacks — and Failed at Alzheimer's

LONGEVITY LATEST ISSUE 12 COMPANION · 27 MAY 2026

LONGEVITY LATEST · DEEP DIVE

The Weight-Loss Drug That Cut Heart Attacks — and Failed at Alzheimer's

What "weight-independent benefit" actually means, and the honest line between treating ageing and treating the diseases it causes.

By Christian Thomsen · Companion to Issue 12 · 27 May 2026 · ~7-minute read

The most interesting result in the GLP-1 story isn't a number. It's a mismatch.

When the SELECT trial cut major cardiovascular events by a fifth in people with obesity but no diabetes, the obvious explanation was the obvious one: they lost weight, and lighter hearts have an easier time. Except the timing was wrong. The event curves started separating within months — earlier than the modest ~9% weight loss could account for — and the benefit tracked a sharp fall in an inflammation marker more tightly than it tracked the pounds. That mismatch launched a thousand think-pieces with the same headline: maybe these aren't weight-loss drugs at all. Maybe they're ageing drugs.

This piece is the verdict to the newsletter's evidence tour. By the end you'll know which of two buckets these drugs belong in — treat a specific disease or longevity fantasy — and which one the wellness internet is quietly selling you.

What a GLP-1 actually does

Glucagon-like peptide-1 is a hormone your gut releases when you eat. Its day job is unglamorous: tell the pancreas to release insulin, slow the stomach, tell the brain you're full. The drugs are engineered versions that resist being broken down, so instead of a post-meal blip you get a steady signal for a week.

That explains the weight loss and the glucose control. What it doesn't explain is the rest of the receptor map. GLP-1 receptors turn up where appetite has nothing to do with it — the lining of blood vessels, the heart, the kidney, immune cells, the brain. Flood the system with a long-acting agonist and you're acting on tissue all over the body, including some of the exact tissues that fail as we age. That's the entire basis of the "ageing drug" idea, and it isn't silly: chronic low-grade inflammation — inflammageing, which we dug into in Issue 05 — is one of the better candidates for a shared mechanism beneath heart disease, kidney decline, and dementia. A drug that genuinely lowered it wouldn't just shrink waistlines. It would touch several diseases of ageing at once.

The receptors are everywhere ageing does its damage. That's the seduction — and the trap.

What the evidence actually supports

On the cardiovascular and kidney side, the case is strong and getting stronger. SELECT (n=17,604) is the anchor: a 20% reduction in heart attack, stroke, and cardiovascular death, in a non-diabetic population, on a hard endpoint. FLOW added a 24% cut in major kidney events. And the inflammation signal is real — across the STEP trials, high-sensitivity CRP fell close to 40%, far more than weight alone predicts.

So "weight-independent benefit" isn't marketing. Its honest form is this: a meaningful share of the cardiovascular gain seems to come from the drug acting directly on the vasculature and the immune system, not merely from a smaller body. That's why cardiologists, not just obesity specialists, now prescribe it.

But "acts on inflammation" is not the same as "slows ageing." Every weight-loss intervention that works lowers inflammation somewhat. The test that separates an ageing drug from a very good metabolic drug is whether the benefit reaches an age-related disease that isn't downstream of metabolism. Which is exactly the test that just ran.

The test that just failed

If the upstream story were the whole truth, Alzheimer's was the place to prove it: a strong neuroinflammatory component, GLP-1 receptors on brain cells, and earlier diabetes-drug data hinting at slower decline. Novo Nordisk ran it properly — EVOKE and EVOKE+, two phase 3 trials, 3,808 people with early Alzheimer's, oral semaglutide versus placebo over roughly two years, published in The Lancet in 2026.

The drug did not slow cognitive or functional decline. Not by a little that missed significance — essentially no drug-placebo difference on the clinical endpoints. Some spinal-fluid biomarkers shifted modestly, which is scientifically interesting and clinically beside the point. The disease progressed the same with the drug as without it.

A drug that cut heart attacks by a fifth did nothing measurable for the ageing brain. Holding both facts at once is the whole discipline.

A true upstream anti-ageing agent should have bent that curve at least a little. It didn't. The defensible reading: GLP-1s are superb across the cardiometabolic cluster — heart, kidney, vasculature, the diseases tightly coupled to metabolism and inflammation — and that does not generalise to every disease of ageing just because the receptors are present.

The frontier — and the catch

The real frontier is narrower and more interesting than "cures ageing." Trials are now testing these drugs in fatty liver disease, specific heart-failure populations (the SUMMIT HFpEF result is genuinely encouraging), osteoarthritis, and addiction, where early signals exist.

The catch is the one nobody markets. We don't know what fifteen years on a GLP-1 does, because nobody has been on one for fifteen years. The longest hard-outcome data runs to a handful of years. For a drug increasingly framed as a lifelong therapy started in midlife, that's the gap that matters — and no amount of mechanistic enthusiasm fills it.

What this means for you

If you have obesity with cardiovascular disease, type 2 diabetes, kidney disease, or sleep apnoea, the calculus is straightforward and the evidence is on your side. That's a different sentence from the one the wellness internet is writing.

If you're chasing these as a general anti-ageing or brain-protective measure, EVOKE is your reality check. These drugs are extraordinary at what they're proven to do and unproven at what they're hoped to do — and the gap between is exactly where money gets wasted and risk gets taken.

So, the one-line summary for a friend: take it for the disease it treats, not the ageing you fear. Protect your muscle while you're on it. And let the fifteen-year data arrive before you decide it's keeping you young — because right now the best evidence says it's keeping your heart healthy, and staying conspicuously quiet about the rest.

This is the Issue 12 Deep Dive. Longevity Latest runs one every week — the long version of the argument the newsletter only has room to start. Next week we audit the most famous supplement stack in the world, pill by pill.

Sources and further reading

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389:2221–2232. PMID: 37952131.

2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine. 2024.

3. SELECT trial investigators. Semaglutide and cardiovascular outcomes by baseline and change in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. 2025.

4. STEP programme investigators. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2 and 3 exploratory analyses). eClinicalMedicine. 2022.

5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205–216. PMID: 35658024.

6. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea (SURMOUNT-OSA). New England Journal of Medicine. 2024.

7. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). New England Journal of Medicine. 2024.

8. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389:514–526. PMID: 37366315.

9. EVOKE and EVOKE+ trial investigators. Efficacy and safety of oral semaglutide 14 mg in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026.

10. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989–1002. PMID: 33567185.

© 2026 FrontWave Media Ltd | Longevity Latest

This article provides information for educational purposes only and is not medical advice. GLP-1 receptor agonists are prescription medicines. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

© 2026 FrontWave Media Ltd · Longevity Latest